Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Comprehensive plasma proteomics reveal three molecular subtypes of transthyretin cardiac amyloidosis linked to distinct prognoses and differential tafamidis treatment responses, highlighting personalized therapeutic opportunities.
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associ